Selected Publications

  1. Yadav R, Leviatan Ben-Arye S, Subramani B, Padler-Karavani V, Kikkeri R. (2016) Screening of Neu5Acα(2-6)gal isomer preferences of siglecs with a sialic acid microarray. Org Biomol Chem 10812-10815. 

  2. Reuven EM, Leviatan Ben-Arye S, Marshanski T, Breimer ME, Yu H, Fellah-Hebia I, Roussel JC, Costa C, Galiñanes M, Mañez R, Le Tourneau T, Soulillou JP, Cozzi E, Chen X, Padler-Karavani V. (2016) Characterization of immunogenic Neu5Gc in bioprosthetic heart valves. Xenotransplantation 381-92.

  3. Amon R, Reuven EM, Leviatan Ben-Arye S, Padler-Karavani V. (2014). Glycans in immune recognition and responseCarbohydr Res. 389:115-22.

  4. Padler-Karavani V#, Hurtado-Ziola N#, Chang YC, Sonnenburg JL, Ronaghy A, Yu H, Verhagen A, Nizet V, Chen X, Varki N, Varki A, Angata T. (2014). Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primatesFASEB J. 28(3):1280-93 (# equally contributed).

  5. UCSD blog: http://ucsdhealthsciences.tumblr.com/post/77737274933/the-red-queen-effect-writ-small-in-what-amountsFeatured on FASEB March 2014 issue; “Scientists Learn How Pathogens Hack Our Immune Systems To Go Undetected”: http://www.eurekalert.org/pub_releases/2014-02/foas-slh022714.php

  6. Padler-Karavani V. (2014). Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicineCancer Lett. 28;352(1):102-12.

  7. Scobie L#, Padler-Karavani V#, Le Bas-Bernardet S, Crossan C, Blaha J, Matouskova M, Hector RD, Cozzi E, Vanhove B, Charreau B, Blancho G, Bourdais L, Tallacchini M, Ribes JM, Yu H, Chen X, Kracikova J, Broz L, Hejnar J, Vesely P, Takeuchi Y, Varki A, Soulillou JP. (2013). Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenograftsJ Immunol. 191(6):2907-15 (# equally contributed).

  8. Kikkeri R, Padler-Karavani V, Diaz S, Verhagen A, Yu H, Cao H, Langereis MA, De Groot RJ, Chen X, Varki A. (2013). Quantum dot nanometal surface energy transfer based biosensing of sialic acid compositions and linkages in biological samplesAnal Chem. 85(8):3864-70

  9. Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. (2013). A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS One. 8(3):e58443.

  10. Wang X, Mitra N, Secundino I, Banda K, Cruz P, Padler-Karavani V, Verhagen A, Reid C, Lari M, Rizzi E, Balsamo C, Corti G, De Bellis G, Longo L; NISC Comparative Sequencing Program, Beggs W, Caramelli D, Tishkoff SA, Hayakawa T, Green ED, Mullikin JC, Nizet V, Bui J, Varki A. (2012). Specific inactivation of two immunomodulatory SIGLEC genes during human evolution.Proc Natl Acad Sci 109(25):9935-40. 

  11. UCSD News release: http://health.ucsd.edu/news/releases/Pages/2012-06-04-infectious-disease-shaped-human-origins.aspx

  12. Padler-Karavani V#, Song X#, Yu H, Hurtado-Ziola N, Huang S, Muthana S, Chokhawala HA, Cheng J, Verhagen A, Langereis MA, Kleene R, Schachner M, de Groot RJ, Lasanajak Y, Matsuda H, Schwab R, Chen X, Smith DF, Cummings RD, Varki A. (2012). Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem. 287(27):22593-608 (# equally contributed).

  13. Lu Q#, Padler-Karavani V#, Yu H, Chen X, Wu S-L, Varki A and Hancock WS. (2012) LC-MS analysis of polyclonal human anti-Neu5Gc Xeno-autoantibodies IgG subclass and partial sequence using multi-step IVIG affinity purification and multi-enzymatic digestionAnal Chem 84(6):2761-8 (# equally contributed).

  14. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancerCancer Res. 71(9):3352-63.

  15. Padler-Karavani V, Varki A. (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection riskXenotransplantation. 18(1):1-5.

  16. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S and Varki A. (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsNat Biotech. 28(8):863-7. 

  17. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V and Varki A. (2010) Novel mechanism for the generation of human xeno-auto-antibodies against the non-human sialic acid N-glycolylneuraminic acidJ Exp Med. 207(8): 1637-1646.

  18. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM and Varki A. (2009) Evidence for a Novel Human-specific Xeno-Auto-Antibody Response Against Vascular EndotheliumBlood. 114(25): 5225-35.

  19. Hedlund M, Padler-Karavani V, Varki N, and Varki A. (2008) Evidence for a Human-Specific Mechanism for Diet and Antibody-Mediated Inflammation in Carcinoma ProgressionProc Natl Acad Sci U S A. 105(48): 18936-41.

  20. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X and Varki A. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for diseaseGlycobiology. 18(10): 818-30.

  21. Aviezer-Hagai K#, Padler-Karavani V#, Nelson N. (2003) Biochemical support for the V-ATPase rotary mechanism: antibody against HA-tagged Vma7p or Vma16p but not Vma10p inhibits activityJ Exp Biol. 206: 3227-37. (# equally contributed).

Contact Details

photo contacts

Mailing address:
Department of Cell Research and Immunology,
Tel-Aviv University,
Ramat Aviv, Tel-Aviv, 69978 Israel

Lab address:
Britannia Building, room 306

Phone:
Lab: +972-3-640-5064
Office: +972-3-640-6737

E-mail:
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Vered Padler-Karavani | Tel Aviv University, Tel Aviv 69978, Israel | Lab: Britannia 306 | Phone: +972-3-640-5064, +972-3-640-6737 | Email: This email address is being protected from spambots. You need JavaScript enabled to view it.